Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Apr;8(3-4):218-31.
doi: 10.1002/prca.201300076. Epub 2014 Feb 19.

The role of O-GlcNAc signaling in the pathogenesis of diabetic retinopathy

Affiliations
Review

The role of O-GlcNAc signaling in the pathogenesis of diabetic retinopathy

Richard D Semba et al. Proteomics Clin Appl. 2014 Apr.

Abstract

Diabetic retinopathy is a leading cause of blindness worldwide. Despite laser and surgical treatments, antiangiogenic and other therapies, and strict metabolic control, many patients progress to visual impairment and blindness. New insights are needed into the pathophysiology of diabetic retinopathy in order to develop new methods to improve the detection and treatment of disease and the prevention of blindness. Hyperglycemia and diabetes result in increased flux through the hexosamine biosynthetic pathway, which, in turn, results in increased PTM of Ser/Thr residues of proteins by O-linked β-N-acetylglucosamine (O-GlcNAc). O-GlcNAcylation is involved in regulation of many nuclear and cytoplasmic proteins in a manner similar to protein phosphorylation. Altered O-GlcNAc signaling has been implicated in the pathogenesis of diabetes and may play an important role in the pathogenesis of diabetic retinopathy. The goal of this review is to summarize the biology of the hexosamine biosynthesis pathway and O-GlcNAc signaling, to present the current evidence for the role of O-GlcNAc signaling in diabetes and diabetic retinopathy, and to discuss future directions for research on O-GlcNAc in the pathogenesis of diabetic retinopathy.

Keywords: Diabetes; Diabetic retinopathy; Glucose toxicity; Hexosamine biosynthesis pathway; O-GlcNAcylation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Relationship of the hexosamine pathway with O-GlcNAcylation of proteins. The rate-limiting enzyme for entry into the pathway is GFAT. The major end product of the pathway is UDP-GlcNAC, which catalyzes the addition of O-GlcNAc to serine and threonine residues of proteins.
Figure 2
Figure 2
The neurovascular unit of the retina, consisting of the close relationship of neurons, glia, and specialized vasculature.
Figure 3
Figure 3
OGA and OGT in diabetic Akita mouse retina. Retinal cryo-sections were prepared from the 5~6-month-old Akita diabetic mice or non-diabetic control mice. Immunofluorescence images of OGA in non-diabetic (A) and control (B) mice. Arrows indicate OGA-positive cells. Immunofluorescence images of OGT in non-diabetic (C) and control (D) mice. GCL: Ganglion cell layer; IPL: inner plexiform layer; INL: inner nuclear layer; OPL: outer plexiform layer; ONL: outer nuclear layer. Counterstaining with diamidino-2-phenylindole (DAPI) was used to highlight the three nuclear layers in the retina: ONL, INL, and GCL.

Similar articles

Cited by

References

    1. Yau JW, Roger SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, Chen SJ, Dekker JM, Fletcher A, Grauslund J, Haffner S, Hamman RF, Ikram MK, Kayama T, Klein BE, Klein R, Krishnaiah S, Mayurasakorn K, O'Hare JP, Orchard TJ, Porta M, Rema M, Roy MS, Sharma T, Mitchell P, Wong TY. Meta-Analysis for Eye Disease (META-EYE) Study Group, Global prevalence and major risk factors for diabetic retinopathy. Diabetes Care. 2012;35:556–564. - PMC - PubMed
    1. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N. Engl. J. Med. 2012;366:1227–1239. - PubMed
    1. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E, Merrifield A, Laatikainen LT, d'Emden MC, O'Connell RL, Colman PG. FIELD Study Investigators, Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370:1687–1697. - PubMed
    1. ACCORD Study Group ACCORD, Eye Study Group. Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC, Jr., Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ. Effects of medical therapies on retinopathy progression in type 2 diabetes. N. Engl. J. Med. 2010;363:233–244. - PMC - PubMed
    1. Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, Boos CJ, Xing W, Egan C, Peto T, Bunce C, Leslie RD, Hykin PG. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010;117:1078–1086.e2. - PubMed

Publication types

MeSH terms

LinkOut - more resources